Impact of Pathologic Complete Response following Neoadjuvant Chemotherapy ± Trastuzumab in Locally Advanced Breast Cancer

Table 2

Pathologic complete response rates in different breast cancer molecular subtypes.

Response	pCR breast (%)	pCR axilla (%)	pCR breast and axilla (%)
Total HER2 negative (n = 434)
ER+/HER2− (278)	17	31	9
ER−/HER2− (156)	37	60	31
Total HER2 positive (n = 247)
ER+/HER2+ (121)	38	50	29
ER−/HER2+ (126)	52	48	37
Total HER2 negative and positive (n = 681)	32	44	23

pCR, pathological complete response; ER, estrogen receptors; PR, progesterone receptors; HER, human epidermal growth factor receptor 2; IHC, immunohistochemistry.